Objective:
Develop approaches to optimize protection from DON in humans by altering the metabolism of this compound.

Approach:
By feeding DON-glucoside to mice, we propose to determine the metabolic fate of this compound by HPLC analysis. By incubating DON-glucoside with human feces and with mouse cecal contents and measuring DON contents by HPLC, we will be able to predict the extent to which this form of DON is likely to be converted to DON in humans and we will determine the usefulness of mouse models in simulating human gut microbial metabolism of this form of DON.